Instrument Inactif

Communiqués Vitrolife AB Nasdaq Stockholm

Actions

SE0000816043

Equipement, fournitures et distribution médicale

Communiqués

16/07	Interim report Q2, 2026: Strong margins and high profitability in soft market conditions	PU
15/07	Vitrolife Group launches SEK 500 million share repurchase programme	AQ
01/07	Invitation to Vitrolife Group's presentation of the Q2 2026 interim report	AQ
01/06	Vitrolife Group appoints Olivier Desmarets as Chief Operations Officer following Ermanno Sironi's retirement	AQ
22/05	CEO Bronwyn Brophy O'Connor has decided to leave Vitrolife Group	AQ
19/05	Vitrolife : Appendix 4 - Approval of the procedure of the Nomination Committee	PU
19/05	Vitrolife : Appendix 6 - Issue of warrants and transfer of warrants to the participants or a third party	PU
19/05	Vitrolife : Appendix 7 - Resolution on authorisation for the Board to resolve to issue shares	PU
19/05	Vitrolife : Appendix 8 - Resolution on authorisation for the Board to resolve on acquisitions of own shares	PU
19/05	Vitrolife : Appendix 9 - Resolution on amendments to the Articles of Association	PU
19/05	Vitrolife : Appendix 10 - Articles of Association for Vitrolife AB (publ)	PU
19/05	Vitrolife : Appendix 5 - Adoption of the plan	PU
19/05	Vitrolife : Appendix 2 - Proposed Agenda	PU
08/05	Vitrolife : App 16a Adoption of the LTIP 2026 plan	PU
08/05	Vitrolife : Minutes AGM 2026	PU
08/05	Vitrolife : App 2 Proposed Agenda	PU
08/05	Vitrolife : App 3 The Board's Remuneration Report	PU
08/05	Vitrolife : App 15 Approval of the procedure of the Nomination Committee	PU
08/05	Vitrolife : App 16b Issue of warrants and transfer of warrants to the participants or a third party	PU
08/05	Vitrolife : App 17 Resolution on authorisation for the Board to resolve to issue shares	PU
08/05	Vitrolife : App 18 Resolution on authorisation for the Board to resolve on acquisitions of own shares	PU
08/05	Vitrolife : App 19 Resolution on amendments to the Articles of Association	PU
05/05	Report from the Annual General Meeting of Vitrolife AB (publ)	AQ
24/04	Vitrolife (Q1 review): Fx-headwind but solid profitability	AQ
23/04	Vitrolife : 23 April 2026, Delårsrapport Q1 2026	PU